H.C. Wainwright reiterates Buy on Rezolute stock, $5 target

H.C. Wainwright reiterated a Buy on Rezolute with a $5.00 price target versus a $3.30 share price, implying about 52% upside. The firm said CGM-based analyses from the Phase 3 sunRIZE study of ersodetug were directionally supportive, even though the trial missed its primary endpoint due to concerns about functional unblinding. Cantor Fitzgerald stayed Neutral, while the FDA is reviewing pathways that could still support approval after receipt of full study reports and datasets.

Analysis

RZLT is becoming a classic litigation-by-data story: the market is no longer pricing the drug on the missed primary endpoint alone, but on whether the company can reframe the dataset into an approvable narrative. The key second-order effect is that objective CGM-style evidence reduces the odds of a full reset trial, which meaningfully shortens the path to a regulatory decision and preserves capital, even if the commercial addressable market is ultimately narrower than the bull case assumes.

The main winner here is time. If the FDA is willing to review full datasets and allow an alternate evidentiary path, the company avoids the usual post-miss death spiral of financing dilution and partner disengagement. The loser is the short thesis built on a binary read-through from the primary endpoint; that trade is vulnerable to incremental regulatory de-risking over the next 1-2 quarters, not just a single approval headline.

The market may still be underestimating two risks: first, the FDA could accept the data package for review without implying approvability, which would leave the stock range-bound for months; second, if the agency insists on additional confirmatory evidence, the company likely needs capital before value realization. In that setup, any rally driven by regulatory optimism can fade if management cannot clearly sequence filing, review, and funding milestones.

The contrarian read is that the strongest trade may not be outright long exposure to RZLT, but optionality around a regulatory rerating. The stock’s current valuation leaves room for a sharp repricing if the agency signals a non-trial path, yet downside remains if the process elongates. That asymmetry favors defined-risk structures over cash equity until the FDA pathway becomes explicit.

Key Decisions for Investors

• Initiate a small starter long in RZLT with a 6-12 month horizon; size for binary regulatory risk and add only if the FDA review path becomes more explicit. Reward/risk is attractive if the stock re-rates toward the analyst band, but treat this as a high-volatility special situation.
• Use call spreads instead of stock for upside exposure: buy 3-6 month RZLT calls and finance with higher strikes to capture a potential regulatory squeeze while limiting downside if the process drags. Best used ahead of catalyst windows rather than after headline spikes.
• For event-driven hedging, pair long RZLT against a basket of small-cap biotech names with no near-term regulatory catalysts. The thesis is that RZLT has a specific de-risking path, while the basket retains generic financing and execution risk.
• If already long, sell into strength on any sharp move tied to FDA optimism and retain a residual position for the filing/review decision. The risk/reward improves on pullbacks, not after momentum squeezes.
• Avoid outright shorting unless the agency clearly rejects the alternate path; near-term data flow is capable of forcing a squeeze, while downside catalysts are more likely to arrive over months than days.